Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.

Abstract: The present invention detects patterns that conform to the user conditions in cases where a disaster recovery constitution is constructed by connecting a plurality of sites. The design system is used in cases where the disaster recovery constitution is provided in a storage system. The site information acquisition section acquires information relating to the constitution in the sites and information relating to the connections between the sites, and stores the information in the site information table. The candidate pattern generation section generates candidate patterns for each of the parameters on the basis of the site information table and a basic pattern table. The candidate pattern evaluation section evaluates the respective candidate patterns by using the user condition table and presents patterns which conform to the user conditions to the user. The document output section generates a construction procedure and operating procedure on the basis of patterns selected by the user.

Abstract: The present inventors succeeded in separating bispecific antibodies that functionally substitute for ligands of type I interferon receptors comprising two types of molecules: AR1 chain and AR2 chain. Furthermore, the present inventors succeeded in producing bispecific antibodies that substitute for the enzyme reaction-accelerating function of blood coagulation factor VIII/activated blood coagulation factor VIII, which bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X.

Abstract: The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII/activated blood coagulation factor VIII which enhances the enzymatic reaction.

Abstract: Formulations for neutralizing the anticoagulant action of a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient; and formulations for neutralizing the blood coagulation-promoting action of an activated blood coagulation factor VII product, comprising a human tissue factor inhibitor as an active ingredient.

Abstract: The compounds of the invention are compounds represented by the following general formula (1): wherein E represents one selected from the group consisting of a methylidyne group and a nitrilo group, R1 represents one selected from the group consisting of optionally substituted aryl groups and optionally substituted heteroaryl groups, R2 represents one selected from the group consisting of a hydrogen atom and alkyl groups, W1 represents an amino acid residue, A represents one selected from the group consisting of a carbonyl group and a sulfonyl group, X1 represents one selected from the group consisting of optionally substituted alkylene groups and optionally substituted alkenylene groups, and p represents 0 or 1; and their pharmacologically acceptable salts, which exhibit thrombopoietin-like activity.

Abstract: In the case when there are two objective biological activities, and the aim is to isolate a compound having at least one biological activity, the present inventors developed an assay method wherein a common detection marker is utilized for separately detecting the presence or absence of each of the biological activities. The present inventors discovered that a compound having at least one of two or more distinct biological activities can be efficiently and conveniently detected by simultaneously assaying at least one test sample or more by the above-mentioned method. Furthermore, for a test sample that proved to be positive by the detection method, they found that it is possible to efficiently and conveniently screen for a test sample having an objective specific biological activity by combining with a method wherein an individual activity of a test sample can be detected to specify the biological activity.

Abstract: The compounds of the invention are compounds represented by the following general formula (1): 1

Abstract: Genes coding for a polypeptide having a human megakaryocyte potentiator activity, recombinant vectors containing said genes, host cells that have been transformed with said recombinant vectors, and a process for producing a polypeptide having a human megakaryocyte potentiator activity by first cultivating said transformed host cells and then isolating the desired polypeptide from the culture.

Abstract: A novel megakaryocyte potentiator (Meg-POT) of human origin is provided. This Meg-POT has a molecular weight of about 32,000 in SDS-PAGE. In addition, this megakaryocyte potentiator contains the following amino acid sequence in its molecule:Gly Glu Thr Gly Gln Glu Ala Ala Pro Leu Asp Gly Val Leu. (SEQ. I.D. No. 1)This Meg-POT is useful as a therapeutic preparation for disorders caused by decreased platelets or platelet hypofunction.

Abstract: A semiconductor light emitting element comprising plural semiconductor layers inclusive of a light emitting part having a pn junction, which are laminated on a crystal substrate, wherein a first semiconductor layer, having a carrier concentration of not more than 5.times.10.sup.17 cm.sup.-3 and a band gap of not less than the energy of the light emitted from the light emitting part, is formed in the passage of the light emitted from the light emitting part toward the substrate side, and a second semiconductor layer, having a carrier concentration of not more than 5.times.10.sup.17 cm.sup.-3 and a band gap of not greater than the energy of the light emitted from the light emitting part, is formed behind (when seen from the passage of the light) the first layer. According to the present invention, sub-peak wavelength light emission can be suppressed to a satisfactory degree.